# Safety and Immunogenicity of MSB11455 in Healthy Participants

> **NCT03251339** · PHASE1 · COMPLETED · sponsor: **Fresenius Kabi SwissBioSim GmbH** · enrollment: 336 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MSB11455
- **DRUG:** US-Neulasta

## Key facts

- **NCT ID:** NCT03251339
- **Lead sponsor:** Fresenius Kabi SwissBioSim GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-21
- **Primary completion:** 2018-02-05
- **Final completion:** 2018-09-22
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251339, "Safety and Immunogenicity of MSB11455 in Healthy Participants". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03251339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*